ChemioCare Inc., a pharmaceutical company working on a proprietary transdermal delivery platform, has closed a private round of financing, raising $★Research Note – Subscriber ONLY content: read our research and get insight on this and other deals. We offer monthly or yearly recurring or one-time trial subscriptions. Subscribe today and see what you have been missing! ★
ChemioCare’s Vision is to transform current treatment of chemotherapy-induced nausea and vomiting through patch technology.
New York City and Vancouver based based ChemioCare is a newly formed BC company.
photo credit: ChemioCare
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Silofit secures $1M seed financing led by Whitecap and Courtside - November 21, 2019
- Novacap Industries V closes at $940M hard cap - November 21, 2019
- Phoenix Molecular Designs closes $12M seed finanicng - November 20, 2019